Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy

Magnetic resonance imaging/Ultrasound ( MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited data is available how to manage patients with a Prostate Imaging-Reporting and Data System (PI-RADS) ≥ 4 lesion and a negative biopsy. We eva...

Full description

Saved in:

Bibliographic Details
Published in	Scientific reports Vol. 12; no. 1; pp. 13603 - 7
Main Authors	Kornienko, Kira, Reuter, Miriam, Maxeiner, Andreas, Günzel, Karsten, Kittner, Beatrice, Reimann, Maximilian, Hofbauer, Sebastian L., Wiemer, Laura E., Heckmann, Robin, Asbach, Patrick, Wendler, Johann Jakob, Schostak, Martin, Schlomm, Thorsten, Friedersdorff, Frank, Cash, Hannes
Format	Journal Article
Language	English
Published	London Nature Publishing Group UK 10.08.2022 Nature Publishing Group Nature Portfolio
Subjects	692/308 692/308/409 692/4025 692/4025/1752 692/4025/2768/1753/466 Biopsy Humanities and Social Sciences Lesions Magnetic resonance imaging multidisciplinary Patients Prostate Prostate cancer Risk assessment Science Science (multidisciplinary) Ultrasonic imaging Ultrasound
Online Access	Get full text

Cover

Loading…

Abstract	Magnetic resonance imaging/Ultrasound ( MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited data is available how to manage patients with a Prostate Imaging-Reporting and Data System (PI-RADS) ≥ 4 lesion and a negative biopsy. We evaluate the real-world management and the rate of clinically significant Prostate Cancer (csPCa) during follow-up. 1546 patients with a multi-parametric MRI (mpMRI) and a PI-RADS ≥ 3 who underwent SB and TB between January 2012 and May 2017 were retrospectively analyzed. 222 men with a PI-RADS ≥ 4 and a negative biopsy were included until 2019. For 177/222 (80%) complete follow-up data was obtained. 66/84 (78%) had an initial PI-RADS 4 and 18 (22%) a PI-RADS 5 lesion. 48% (84/177) received a repeat mpMRI; in the follow-up mpMRI, 39/84 (46%) lesions were downgraded to PI-RADS 2 and 11 (13%) to PI-RADS 3; three cases were upgraded and 28 lesions remained consistent. 18% (32/177) men underwent repeated TB and csPCa was detected in 44% (14/32). Our study presents real world data on the management of men with a negative TB biopsy. Men with a positive mpMRI and lesions with high suspicion (PI-RADS4/5) and a negative targeted biopsy should be critically reviewed and considered for repeat biopsy or strict surveillance. The optimal clinical risk assessment remains to be further evaluated.
AbstractList	Magnetic resonance imaging/Ultrasound ( MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited data is available how to manage patients with a Prostate Imaging-Reporting and Data System (PI-RADS) ≥ 4 lesion and a negative biopsy. We evaluate the real-world management and the rate of clinically significant Prostate Cancer (csPCa) during follow-up. 1546 patients with a multi-parametric MRI (mpMRI) and a PI-RADS ≥ 3 who underwent SB and TB between January 2012 and May 2017 were retrospectively analyzed. 222 men with a PI-RADS ≥ 4 and a negative biopsy were included until 2019. For 177/222 (80%) complete follow-up data was obtained. 66/84 (78%) had an initial PI-RADS 4 and 18 (22%) a PI-RADS 5 lesion. 48% (84/177) received a repeat mpMRI; in the follow-up mpMRI, 39/84 (46%) lesions were downgraded to PI-RADS 2 and 11 (13%) to PI-RADS 3; three cases were upgraded and 28 lesions remained consistent. 18% (32/177) men underwent repeated TB and csPCa was detected in 44% (14/32). Our study presents real world data on the management of men with a negative TB biopsy. Men with a positive mpMRI and lesions with high suspicion (PI-RADS4/5) and a negative targeted biopsy should be critically reviewed and considered for repeat biopsy or strict surveillance. The optimal clinical risk assessment remains to be further evaluated. Magnetic resonance imaging/Ultrasound (MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited data is available how to manage patients with a Prostate Imaging-Reporting and Data System (PI-RADS) ≥ 4 lesion and a negative biopsy. We evaluate the real-world management and the rate of clinically significant Prostate Cancer (csPCa) during follow-up. 1546 patients with a multi-parametric MRI (mpMRI) and a PI-RADS ≥ 3 who underwent SB and TB between January 2012 and May 2017 were retrospectively analyzed. 222 men with a PI-RADS ≥ 4 and a negative biopsy were included until 2019. For 177/222 (80%) complete follow-up data was obtained. 66/84 (78%) had an initial PI-RADS 4 and 18 (22%) a PI-RADS 5 lesion. 48% (84/177) received a repeat mpMRI; in the follow-up mpMRI, 39/84 (46%) lesions were downgraded to PI-RADS 2 and 11 (13%) to PI-RADS 3; three cases were upgraded and 28 lesions remained consistent. 18% (32/177) men underwent repeated TB and csPCa was detected in 44% (14/32). Our study presents real world data on the management of men with a negative TB biopsy. Men with a positive mpMRI and lesions with high suspicion (PI-RADS4/5) and a negative targeted biopsy should be critically reviewed and considered for repeat biopsy or strict surveillance. The optimal clinical risk assessment remains to be further evaluated.Magnetic resonance imaging/Ultrasound (MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited data is available how to manage patients with a Prostate Imaging-Reporting and Data System (PI-RADS) ≥ 4 lesion and a negative biopsy. We evaluate the real-world management and the rate of clinically significant Prostate Cancer (csPCa) during follow-up. 1546 patients with a multi-parametric MRI (mpMRI) and a PI-RADS ≥ 3 who underwent SB and TB between January 2012 and May 2017 were retrospectively analyzed. 222 men with a PI-RADS ≥ 4 and a negative biopsy were included until 2019. For 177/222 (80%) complete follow-up data was obtained. 66/84 (78%) had an initial PI-RADS 4 and 18 (22%) a PI-RADS 5 lesion. 48% (84/177) received a repeat mpMRI; in the follow-up mpMRI, 39/84 (46%) lesions were downgraded to PI-RADS 2 and 11 (13%) to PI-RADS 3; three cases were upgraded and 28 lesions remained consistent. 18% (32/177) men underwent repeated TB and csPCa was detected in 44% (14/32). Our study presents real world data on the management of men with a negative TB biopsy. Men with a positive mpMRI and lesions with high suspicion (PI-RADS4/5) and a negative targeted biopsy should be critically reviewed and considered for repeat biopsy or strict surveillance. The optimal clinical risk assessment remains to be further evaluated. Magnetic resonance imaging/Ultrasound (MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited data is available how to manage patients with a Prostate Imaging-Reporting and Data System (PI-RADS) ≥ 4 lesion and a negative biopsy. We evaluate the real-world management and the rate of clinically significant Prostate Cancer (csPCa) during follow-up. 1546 patients with a multi-parametric MRI (mpMRI) and a PI-RADS ≥ 3 who underwent SB and TB between January 2012 and May 2017 were retrospectively analyzed. 222 men with a PI-RADS ≥ 4 and a negative biopsy were included until 2019. For 177/222 (80%) complete follow-up data was obtained. 66/84 (78%) had an initial PI-RADS 4 and 18 (22%) a PI-RADS 5 lesion. 48% (84/177) received a repeat mpMRI; in the follow-up mpMRI, 39/84 (46%) lesions were downgraded to PI-RADS 2 and 11 (13%) to PI-RADS 3; three cases were upgraded and 28 lesions remained consistent. 18% (32/177) men underwent repeated TB and csPCa was detected in 44% (14/32). Our study presents real world data on the management of men with a negative TB biopsy. Men with a positive mpMRI and lesions with high suspicion (PI-RADS4/5) and a negative targeted biopsy should be critically reviewed and considered for repeat biopsy or strict surveillance. The optimal clinical risk assessment remains to be further evaluated. Abstract Magnetic resonance imaging/Ultrasound (MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited data is available how to manage patients with a Prostate Imaging-Reporting and Data System (PI-RADS) ≥ 4 lesion and a negative biopsy. We evaluate the real-world management and the rate of clinically significant Prostate Cancer (csPCa) during follow-up. 1546 patients with a multi-parametric MRI (mpMRI) and a PI-RADS ≥ 3 who underwent SB and TB between January 2012 and May 2017 were retrospectively analyzed. 222 men with a PI-RADS ≥ 4 and a negative biopsy were included until 2019. For 177/222 (80%) complete follow-up data was obtained. 66/84 (78%) had an initial PI-RADS 4 and 18 (22%) a PI-RADS 5 lesion. 48% (84/177) received a repeat mpMRI; in the follow-up mpMRI, 39/84 (46%) lesions were downgraded to PI-RADS 2 and 11 (13%) to PI-RADS 3; three cases were upgraded and 28 lesions remained consistent. 18% (32/177) men underwent repeated TB and csPCa was detected in 44% (14/32). Our study presents real world data on the management of men with a negative TB biopsy. Men with a positive mpMRI and lesions with high suspicion (PI-RADS4/5) and a negative targeted biopsy should be critically reviewed and considered for repeat biopsy or strict surveillance. The optimal clinical risk assessment remains to be further evaluated.
ArticleNumber	13603
Author	Friedersdorff, Frank Asbach, Patrick Schostak, Martin Kornienko, Kira Hofbauer, Sebastian L. Reuter, Miriam Kittner, Beatrice Wendler, Johann Jakob Schlomm, Thorsten Wiemer, Laura E. Reimann, Maximilian Maxeiner, Andreas Günzel, Karsten Cash, Hannes Heckmann, Robin
Author_xml	– sequence: 1 givenname: Kira surname: Kornienko fullname: Kornienko, Kira organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 2 givenname: Miriam surname: Reuter fullname: Reuter, Miriam organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 3 givenname: Andreas surname: Maxeiner fullname: Maxeiner, Andreas organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 4 givenname: Karsten surname: Günzel fullname: Günzel, Karsten organization: Department of Urology, Vivantes Am Urban – sequence: 5 givenname: Beatrice surname: Kittner fullname: Kittner, Beatrice organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 6 givenname: Maximilian surname: Reimann fullname: Reimann, Maximilian organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 7 givenname: Sebastian L. surname: Hofbauer fullname: Hofbauer, Sebastian L. organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 8 givenname: Laura E. surname: Wiemer fullname: Wiemer, Laura E. organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 9 givenname: Robin surname: Heckmann fullname: Heckmann, Robin organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 10 givenname: Patrick surname: Asbach fullname: Asbach, Patrick organization: Clinic for Radiology, Charité-Universitätsmedizin Berlin – sequence: 11 givenname: Johann Jakob surname: Wendler fullname: Wendler, Johann Jakob organization: Department of Urology, University Magdeburg – sequence: 12 givenname: Martin surname: Schostak fullname: Schostak, Martin organization: Department of Urology, University Magdeburg – sequence: 13 givenname: Thorsten surname: Schlomm fullname: Schlomm, Thorsten organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 14 givenname: Frank surname: Friedersdorff fullname: Friedersdorff, Frank organization: Department of Urology, Charité-Universitätsmedizin Berlin – sequence: 15 givenname: Hannes surname: Cash fullname: Cash, Hannes email: hannes.cash@prouro.de organization: Department of Urology, Charité-Universitätsmedizin Berlin, Department of Urology, University Magdeburg, PROURO
BookMark	eNp9Uk1P3DAUtCoqoJQ_0JOlXnpJ19-OL5UQlHYlUCtauFpO4ixeee2tnYD493U2VAUO-GA_2TPjN0_zDuyFGCwAHzD6jBGtF5lhruoKEVJhSQSqxBtwSBDjFaGE7D2pD8BxzmtUFieKYbUPDihXrOaSH4Kb8-h9vK_GLYw93NgA791wCw38uayuTs5-Qbbg0NvsYoCmH2yCwa7M4O4svLxaLq79kEyOY-hgP-5AjYvb_PAevO2Nz_b48TwC1-dff59-ry5-fFuenlxULcdyqCjqiTKsN01NMSMdVYwrWXbFO0Y7IzssGiN5zRG3qsWCoOJK9hLZgu8oPQLLWbeLZq23yW1MetDROL27iGmlTRpc660WhlODlTCMSiaUbBopLe4aQQVuGGuL1pdZazs2G9u1NhRv_pno85fgbvUq3mlFBZdSFIFPjwIp_hltHvTG5dZ6b4KNY9ZEIowklZQV6McX0HUcUyijmlDFI8ZiclfPqDbFnJPtdeuGMvw4_e-8xkhPWdBzFnTJgt5lQU-9kBfUfz5eJdGZlAs4rGz639UrrL83IsNM
CitedBy_id	crossref_primary_10_1002_pros_24764 crossref_primary_10_1016_j_crad_2023_10_008 crossref_primary_10_3390_cancers17020277 crossref_primary_10_1007_s00261_023_04011_y crossref_primary_10_1016_j_euros_2022_11_013 crossref_primary_10_1007_s00261_024_04783_x crossref_primary_10_1186_s13244_024_01651_6 crossref_primary_10_1001_jamaoncol_2024_5497 crossref_primary_10_1007_s00330_024_10702_x crossref_primary_10_1007_s00330_025_11479_3 crossref_primary_10_1016_j_purol_2023_10_001 crossref_primary_10_1016_j_euf_2023_03_011 crossref_primary_10_1016_j_clgc_2025_102308
Cites_doi	10.1016/j.eururo.2016.12.006 10.1111/bju.13327 10.1016/j.juro.2017.03.131 10.1016/j.juro.2014.07.098 10.1007/s00345-015-1671-8 10.1016/j.ejrad.2019.01.030 10.1200/JCO.2020.38.6_suppl.288 10.1016/j.eururo.2018.03.007 10.1016/j.juro.2018.05.003 10.1007/s00330-020-06929-z 10.1097/JU.0000000000001232 10.1016/j.juro.2016.06.079 10.1016/j.ucl.2014.01.010 10.1016/j.urolonc.2019.01.030 10.1097/JU.0000000000001424 10.1097/JU.0000000000000757 10.1097/JU.0000000000000617 10.1016/j.eururo.2016.08.003 10.1159/000477263 10.1016/j.clgc.2020.04.001 10.1016/S0140-6736(16)32401-1 10.1111/j.1464-410X.2012.11607.x 10.1016/S0022-5347(05)66347-1 10.1016/j.eururo.2013.03.030 10.1056/NEJMoa1801993 10.1111/bju.14212 10.1016/j.eururo.2019.06.023
ContentType	Journal Article
Copyright	The Author(s) 2022 The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s).
Copyright_xml	– notice: The Author(s) 2022 – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s).
DBID	C6C AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 5PM DOA
DOI	10.1038/s41598-022-17260-6
DatabaseName	Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE - Academic Publicly Available Content Database
Database_xml	– sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2045-2322
EndPage	7
ExternalDocumentID	oai_doaj_org_article_6a53a196a4374697bb77e1db6361b44c PMC9365776 10_1038_s41598_022_17260_6
GrantInformation_xml	– fundername: Otto-von-Guericke-Universität Magdeburg (3121) – fundername: ;
GroupedDBID	0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT 7XB 8FK AARCD K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI Q9U 7X8 5PM PUEGO
ID	FETCH-LOGICAL-c517t-30f29a4fab83142d39459739495d43da7d16ba758505e9c16200457f70e314d33
IEDL.DBID	M48
ISSN	2045-2322
IngestDate	Wed Aug 27 01:32:44 EDT 2025 Thu Aug 21 13:55:18 EDT 2025 Fri Jul 11 08:13:44 EDT 2025 Wed Aug 13 05:15:39 EDT 2025 Thu Apr 24 23:08:33 EDT 2025 Tue Jul 01 04:17:03 EDT 2025 Fri Feb 21 02:40:21 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c517t-30f29a4fab83142d39459739495d43da7d16ba758505e9c16200457f70e314d33
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-022-17260-6
PMID	35948575
PQID	2700451163
PQPubID	2041939
PageCount	7
ParticipantIDs	doaj_primary_oai_doaj_org_article_6a53a196a4374697bb77e1db6361b44c pubmedcentral_primary_oai_pubmedcentral_nih_gov_9365776 proquest_miscellaneous_2701073734 proquest_journals_2700451163 crossref_citationtrail_10_1038_s41598_022_17260_6 crossref_primary_10_1038_s41598_022_17260_6 springer_journals_10_1038_s41598_022_17260_6
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2022-08-10
PublicationDateYYYYMMDD	2022-08-10
PublicationDate_xml	– month: 08 year: 2022 text: 2022-08-10 day: 10
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London
PublicationTitle	Scientific reports
PublicationTitleAbbrev	Sci Rep
PublicationYear	2022
Publisher	Nature Publishing Group UK Nature Publishing Group Nature Portfolio
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio
References	Bjurlin, Carroll, Eggener, Fulgham, Margolis, Pinto (CR3) 2019 Pepe, Pennisi (CR25) 2020 Rosenkrantz, Verma, Choyke, Eberhardt, Eggener, Gaitonde (CR1) 2016; 196 Cash, Maxeiner, Stephan, Fischer, Durmus, Holzmann (CR5) 2016; 34 Kinnaird, Sharma, Chuang, Priester, Tran, Barsa (CR19) 2020 Cash, Gunzel, Maxeiner, Stephan, Fischer, Durmus (CR24) 2016; 118 Drost, Osses, Nieboer, Bangma, Steyerberg, Roobol (CR14) 2019 Ullrich, Arsov, Quentin, Laqua, Klingebiel, Martin (CR23) 2019; 113 Panebianco, Barchetti, Simone, Del Monte, Ciardi, Grompone (CR21) 2018; 74 Kasivisvanathan, Rannikko, Borghi, Panebianco, Mynderse, Vaarala (CR12) 2018; 378 Moore, Kasivisvanathan, Eggener, Emberton, Fütterer, Gill (CR17) 2013; 64 Shinohara, Nguyen, Masic (CR9) 2014; 41 Maxeiner, Kittner, Blobel, Wiemer, Hofbauer, Fischer (CR16) 2018; 122 Schouten, van der Leest, Pokorny, Hoogenboom, Barentsz, Thompson (CR20) 2017; 71 Mottet, Bellmunt, Bolla, Briers, Cumberbatch, De Santis (CR2) 2017; 71 Gore, Shariat, Miles, Kadmon, Jiang, Wheeler (CR8) 2001; 165 Sayyid, Alibhai, Sutradhar, Eberg, Fung, Klaassen (CR10) 2019; 37 Ahmed, El-Shater Bosaily, Brown, Gabe, Kaplan, Parmar (CR11) 2017; 389 Mehralivand, Bednarova, Shih, Mertan, Gaur, Merino (CR15) 2017; 198 Twum-Ampofo, Ceraolo, Gusev, Feldman (CR26) 2020; 38 Meng, Chao, Chen, Huang, Taneja, Deng (CR27) 2020 CR22 Ploussard, Nicolaiew, Marchand, Terry, Allory, Vacherot (CR28) 2013; 111 Hofbauer, Maxeiner, Kittner, Heckmann, Reimann, Wiemer (CR6) 2018; 200 de Rooij (CR18) 2020; 30 Borkowetz, Platzek, Toma, Renner, Herout, Baunacke (CR4) 2017; 99 Pagniez, Kasivisvanathan, Puech, Drumez, Villers, Olivier (CR13) 2020; 204 Radtke, Kuru, Boxler, Alt, Popeneciu, Huettenbrink (CR7) 2015; 193 T Ullrich (17260_CR23) 2019; 113 CM Moore (17260_CR17) 2013; 64 FH Drost (17260_CR14) 2019 SL Hofbauer (17260_CR6) 2018; 200 JL Gore (17260_CR8) 2001; 165 JP Radtke (17260_CR7) 2015; 193 A Borkowetz (17260_CR4) 2017; 99 MA Pagniez (17260_CR13) 2020; 204 A Maxeiner (17260_CR16) 2018; 122 17260_CR22 A Kinnaird (17260_CR19) 2020 K Shinohara (17260_CR9) 2014; 41 MG Schouten (17260_CR20) 2017; 71 HU Ahmed (17260_CR11) 2017; 389 H Cash (17260_CR24) 2016; 118 X Meng (17260_CR27) 2020 V Kasivisvanathan (17260_CR12) 2018; 378 P Pepe (17260_CR25) 2020 RK Sayyid (17260_CR10) 2019; 37 J Twum-Ampofo (17260_CR26) 2020; 38 N Mottet (17260_CR2) 2017; 71 MA Bjurlin (17260_CR3) 2019 M de Rooij (17260_CR18) 2020; 30 V Panebianco (17260_CR21) 2018; 74 S Mehralivand (17260_CR15) 2017; 198 H Cash (17260_CR5) 2016; 34 G Ploussard (17260_CR28) 2013; 111 AB Rosenkrantz (17260_CR1) 2016; 196
References_xml	– volume: 71 start-page: 896 year: 2017 end-page: 903 ident: CR20 article-title: Why and where do we miss significant prostate cancer with multi-parametric magnetic resonance imaging followed by magnetic resonance-guided and transrectal ultrasound-guided biopsy in biopsy-naive men? publication-title: Eur. Urol. doi: 10.1016/j.eururo.2016.12.006 – ident: CR22 – volume: 118 start-page: 35 year: 2016 end-page: 43 ident: CR24 article-title: Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: Reasons for targeted biopsy failure publication-title: BJU Int. doi: 10.1111/bju.13327 – volume: 198 start-page: 583 year: 2017 end-page: 590 ident: CR15 article-title: Prospective evaluation of PI-RADS version 2 using the international society of urological pathology prostate cancer grade group system publication-title: J. Urol. doi: 10.1016/j.juro.2017.03.131 – volume: 193 start-page: 87 year: 2015 end-page: 94 ident: CR7 article-title: Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance publication-title: J. Urol. doi: 10.1016/j.juro.2014.07.098 – volume: 34 start-page: 525 year: 2016 end-page: 532 ident: CR5 article-title: The detection of significant prostate cancer is correlated with the prostate imaging reporting and data system (PI-RADS) in MRI/transrectal ultrasound fusion biopsy publication-title: World J. Urol. doi: 10.1007/s00345-015-1671-8 – volume: 113 start-page: 1 year: 2019 end-page: 6 ident: CR23 article-title: Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients publication-title: Eur. J. Radiol. doi: 10.1016/j.ejrad.2019.01.030 – volume: 38 start-page: 288 year: 2020 end-page: 288 ident: CR26 article-title: Detection of clinically significant prostate cancer after negative fusion and systematic biopsy publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.6_suppl.288 – volume: 74 start-page: 48 year: 2018 end-page: 54 ident: CR21 article-title: Negative multiparametric magnetic resonance imaging for prostate cancer: What’s next? publication-title: Eur. Urol. doi: 10.1016/j.eururo.2018.03.007 – volume: 200 start-page: 767 year: 2018 end-page: 773 ident: CR6 article-title: Validation of prostate imaging reporting and data system version 2 for the detection of prostate cancer publication-title: J. Urol. doi: 10.1016/j.juro.2018.05.003 – volume: 30 start-page: 5404 year: 2020 end-page: 5416 ident: CR18 article-title: ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: Quality requirements for image acquisition, interpretation and radiologists’ training publication-title: Eur. Radiol. doi: 10.1007/s00330-020-06929-z – year: 2020 ident: CR19 article-title: Risk of prostate cancer after a negative magnetic resonance imaging guided biopsy publication-title: J. Urol. doi: 10.1097/JU.0000000000001232 – volume: 196 start-page: 1613 year: 2016 end-page: 1618 ident: CR1 article-title: prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: A consensus statement by AUA and SAR publication-title: J. Urol. doi: 10.1016/j.juro.2016.06.079 – volume: 41 start-page: 327 year: 2014 end-page: 338 ident: CR9 article-title: Management of an increasing prostate-specific antigen level after negative prostate biopsy publication-title: Urol. Clin. North Am. doi: 10.1016/j.ucl.2014.01.010 – volume: 37 start-page: 298 e19 year: 2019 end-page: 298 e27 ident: CR10 article-title: Population-based outcomes of men with a single negative prostate biopsy: Importance of continued follow-up among older patients publication-title: Urol. Oncol. doi: 10.1016/j.urolonc.2019.01.030 – year: 2020 ident: CR27 article-title: Follow-up of men with PI-RADS 4 or 5 abnormality on prostate MRI and nonmalignant pathologic findings on initial targeted prostate biopsy publication-title: J. Urol. doi: 10.1097/JU.0000000000001424 – volume: 204 start-page: 24 year: 2020 end-page: 32 ident: CR13 article-title: Predictive factors of missed clinically significant prostate cancers in men with negative magnetic resonance imaging: A systematic review and meta-analysis publication-title: J. Urol. doi: 10.1097/JU.0000000000000757 – year: 2019 ident: CR3 article-title: Update of the AUA policy statement on the use of multiparametric magnetic resonance imaging in the diagnosis, staging and management of prostate cancer publication-title: J. Urol. doi: 10.1097/JU.0000000000000617 – volume: 71 start-page: 618 year: 2017 end-page: 629 ident: CR2 article-title: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent publication-title: Eur. Urol. doi: 10.1016/j.eururo.2016.08.003 – volume: 99 start-page: 177 year: 2017 end-page: 185 ident: CR4 article-title: Evaluation of prostate imaging reporting and data system classification in the prediction of tumor aggressiveness in targeted magnetic resonance imaging/ultrasound-fusion biopsy publication-title: Urol. Int. doi: 10.1159/000477263 – year: 2020 ident: CR25 article-title: Negative biopsy histology in men with PI-RADS score 5 in daily clinical practice: Incidence of granulomatous prostatitis publication-title: Clin. Genitourin. Cancer. doi: 10.1016/j.clgc.2020.04.001 – volume: 389 start-page: 815 year: 2017 end-page: 822 ident: CR11 article-title: Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study publication-title: Lancet doi: 10.1016/S0140-6736(16)32401-1 – volume: 111 start-page: 988 year: 2013 end-page: 996 ident: CR28 article-title: Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: Longitudinal follow-up from a prospective trial publication-title: BJU Int. doi: 10.1111/j.1464-410X.2012.11607.x – volume: 165 start-page: 1554 year: 2001 end-page: 1559 ident: CR8 article-title: Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer publication-title: J. Urol. doi: 10.1016/S0022-5347(05)66347-1 – volume: 64 start-page: 544 year: 2013 end-page: 552 ident: CR17 article-title: Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: Recommendations from an international working group publication-title: Eur. Urol. doi: 10.1016/j.eururo.2013.03.030 – volume: 378 start-page: 1767 year: 2018 end-page: 1777 ident: CR12 article-title: MRI-targeted or standard biopsy for prostate-cancer diagnosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801993 – volume: 122 start-page: 211 year: 2018 end-page: 218 ident: CR16 article-title: Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate publication-title: BJU Int. doi: 10.1111/bju.14212 – year: 2019 ident: CR14 article-title: Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: A cochrane systematic review and meta-analysis publication-title: Eur. Urol. doi: 10.1016/j.eururo.2019.06.023 – volume: 74 start-page: 48 year: 2018 ident: 17260_CR21 publication-title: Eur. Urol. doi: 10.1016/j.eururo.2018.03.007 – volume: 165 start-page: 1554 year: 2001 ident: 17260_CR8 publication-title: J. Urol. doi: 10.1016/S0022-5347(05)66347-1 – volume: 37 start-page: 298 e19 year: 2019 ident: 17260_CR10 publication-title: Urol. Oncol. doi: 10.1016/j.urolonc.2019.01.030 – volume: 198 start-page: 583 year: 2017 ident: 17260_CR15 publication-title: J. Urol. doi: 10.1016/j.juro.2017.03.131 – volume: 118 start-page: 35 year: 2016 ident: 17260_CR24 publication-title: BJU Int. doi: 10.1111/bju.13327 – volume: 64 start-page: 544 year: 2013 ident: 17260_CR17 publication-title: Eur. Urol. doi: 10.1016/j.eururo.2013.03.030 – ident: 17260_CR22 – volume: 389 start-page: 815 year: 2017 ident: 17260_CR11 publication-title: Lancet doi: 10.1016/S0140-6736(16)32401-1 – volume: 204 start-page: 24 year: 2020 ident: 17260_CR13 publication-title: J. Urol. doi: 10.1097/JU.0000000000000757 – year: 2019 ident: 17260_CR3 publication-title: J. Urol. doi: 10.1097/JU.0000000000000617 – volume: 41 start-page: 327 year: 2014 ident: 17260_CR9 publication-title: Urol. Clin. North Am. doi: 10.1016/j.ucl.2014.01.010 – year: 2020 ident: 17260_CR27 publication-title: J. Urol. doi: 10.1097/JU.0000000000001424 – volume: 113 start-page: 1 year: 2019 ident: 17260_CR23 publication-title: Eur. J. Radiol. doi: 10.1016/j.ejrad.2019.01.030 – volume: 196 start-page: 1613 year: 2016 ident: 17260_CR1 publication-title: J. Urol. doi: 10.1016/j.juro.2016.06.079 – volume: 71 start-page: 618 year: 2017 ident: 17260_CR2 publication-title: Eur. Urol. doi: 10.1016/j.eururo.2016.08.003 – volume: 71 start-page: 896 year: 2017 ident: 17260_CR20 publication-title: Eur. Urol. doi: 10.1016/j.eururo.2016.12.006 – volume: 122 start-page: 211 year: 2018 ident: 17260_CR16 publication-title: BJU Int. doi: 10.1111/bju.14212 – volume: 30 start-page: 5404 year: 2020 ident: 17260_CR18 publication-title: Eur. Radiol. doi: 10.1007/s00330-020-06929-z – volume: 38 start-page: 288 year: 2020 ident: 17260_CR26 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.6_suppl.288 – volume: 99 start-page: 177 year: 2017 ident: 17260_CR4 publication-title: Urol. Int. doi: 10.1159/000477263 – volume: 378 start-page: 1767 year: 2018 ident: 17260_CR12 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801993 – year: 2020 ident: 17260_CR19 publication-title: J. Urol. doi: 10.1097/JU.0000000000001232 – volume: 193 start-page: 87 year: 2015 ident: 17260_CR7 publication-title: J. Urol. doi: 10.1016/j.juro.2014.07.098 – volume: 111 start-page: 988 year: 2013 ident: 17260_CR28 publication-title: BJU Int. doi: 10.1111/j.1464-410X.2012.11607.x – volume: 34 start-page: 525 year: 2016 ident: 17260_CR5 publication-title: World J. Urol. doi: 10.1007/s00345-015-1671-8 – volume: 200 start-page: 767 year: 2018 ident: 17260_CR6 publication-title: J. Urol. doi: 10.1016/j.juro.2018.05.003 – year: 2019 ident: 17260_CR14 publication-title: Eur. Urol. doi: 10.1016/j.eururo.2019.06.023 – year: 2020 ident: 17260_CR25 publication-title: Clin. Genitourin. Cancer. doi: 10.1016/j.clgc.2020.04.001
SSID	ssj0000529419
Score	2.4514334
Snippet	Magnetic resonance imaging/Ultrasound ( MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited... Magnetic resonance imaging/Ultrasound (MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited... Abstract Magnetic resonance imaging/Ultrasound (MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but...
SourceID	doaj pubmedcentral proquest crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher
StartPage	13603
SubjectTerms	692/308 692/308/409 692/4025 692/4025/1752 692/4025/2768/1753/466 Biopsy Humanities and Social Sciences Lesions Magnetic resonance imaging multidisciplinary Patients Prostate Prostate cancer Risk assessment Science Science (multidisciplinary) Ultrasonic imaging Ultrasound
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOgl9EncpkWB3lKxlvWyjuljSQoJJe2G3IRkSW1gay_dXUr-fUeydxMH0l568cEeW9JoxjOjkb5B6C14AA3VipKK-5Jw1TCinY6klr4MoY5CsXTA-fRMHs_450txeavUV9oT1sMD94ybSCuYBTGxnCkI5ZRzSgXqnWSSOs6b9PcFm3crmOpRvSvNqR5OyZSsnizBUqXTZBB7gc2WEDONLFEG7B95mXf3SN5JlGb7M32MdgfHER_1HX6CHoT2KXrYl5K8foYupjCh3W-yXuAu4p-hxWmFFVv85YScH338ivlE4HlIa2M41wXHbfieQb_x6fnJZDaH5pepxBKO60zkrrrF8vo5mk0_fftwTIaaCaQRVK0IK2OlLY_W1YzyyjPNIWSAqxaeM2-Vp9LZFCSUIuiGyqQlQkVVBqD3jL1AO23Xhj2EfRSxCuCgwDdBs73Lx3y1EJYnr0cViG74Z5oBUDzVtZibnNhmtel5boDnJvPcyAIdbt9Z9HAaf6V-n6ZlS5mgsPMNEBAzCIj5l4AUaH8zqWbQz6VJ6faEzCZZgQ62j0GzUrrEtqFbZxqIjZlivEBqJAyjDo2ftFc_Mka3ZlIoBSN4txGbm8bvH_DL_zHgV-hRlcQ84_buo53Vr3V4DZ7Tyr3JSvIHPXAOoQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4ilCCzISN7A2iV_xCZXHqkUqQoVFe7Ps2CmVlmTb7Ar13zPjzW6VSvSSQzyJXzP2POxvCHkLGkBdGF2wUoScCV1zZrxpWKVCHmPVSM3xgvPJN3U0E1_ncj443PrhWOV2TUwLdehq9JFPMECKWFqKf1heMMwahdHVIYXGXXIPocuQq_Vc73wsGMUShRnuyuS8mvSwX-GdMrDAYOdWYDmN9qME2z_SNW-elLwRLk270PQReTioj_RwM9-PyZ3YPiH3Nwklr56SX1OY1u4vWy9p19A_saXoZ6WOfj9mp4eff1AxkXQR0UNGU3Zw2sazBP1NT06PJ7MFVN9joiXarBORP--W_dUzMpt--fnpiA2ZE1gtC71iPG9K40TjfMULUQZuBBgO8DQyCB6cDoXyDk2FXEZTFwplRepG5xHoA-fPyV7btfEFoaGRTRlBTYF_gnwHny77GimdQN1HZ6TYjp-tB1hxzG6xsCm8zSu7GXMLY27TmFuVkXe7b5YbUI1bqT_itOwoERA7veguz-wgX1Y5yR2sJk5wDRa_9l7rWASvuCq8EHVGDraTagcp7e01T2Xkza4Y5AuDJq6N3TrRgIXMNRcZ0SNmGDVoXNKe_05I3YYrqTX04P2Wba4r_3-HX97e1n3yoEQGTri8B2RvdbmOr0AzWvnXif3_AeBsBq8 priority: 102 providerName: ProQuest – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyQuiKcIFGQkbmBtHL_i4_JYtSsVoZZFvVl2bJdKJVl1d4X67xl7k0WpAIlLDvE48WPGnvF4vkHoDWgADdWKkor7knDVMKKdjqSWvgyhjkKxFOB88lkeLfj8XJzvoWqIhcmX9jOkZV6mh9thkxVsNCkYDEwn2HIlmDx30EGCagfePphO52fz3clK8l1xqvsImZLVf6g82oUyWP9Iw7x9P_KWkzTvPbMH6H6vNOLptpkP0V5oH6G72zSSN4_RtxlMZveTbJa4i_hHaHE6XcUWfzkmp9OPZ5hPBIbuwRTgnBMct-EiA37jk9PjyeIKfr9K6ZVw3GQid9ktVzdP0GL26euHI9LnSyCNoGpNWBkrbXm0rmaUV55pDuYCPLXwnHmrPJXOJgOhFEE3VCYJESqqMgC9Z-wp2m-7NjxD2EcRqwDKCXwTpNq7HOKrhbA8aTyqQHQYP9P0YOIpp8WVyU5tVpvtmBsYc5PH3MgCvd3VWW6hNP5J_T5Ny44ywWDnF931henZwkgrmIU1xHKmwM5XzikVqHeSSeo4bwp0OEyq6WVzZZKrPaGySVag17tikKrkKrFt6DaZBuxiphgvkBoxw6hB45L28nvG59ZMCqWgB-8Gtvn98793-Pn_kb9A96rE0Bmd9xDtr6834SXoR2v3qheIX5VUBe4 priority: 102 providerName: Springer Nature
Title	Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy
URI	https://link.springer.com/article/10.1038/s41598-022-17260-6 https://www.proquest.com/docview/2700451163 https://www.proquest.com/docview/2701073734 https://pubmed.ncbi.nlm.nih.gov/PMC9365776 https://doaj.org/article/6a53a196a4374697bb77e1db6361b44c
Volume	12
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Za9tAEF5yUOhLSS-qJjVb6Fu7taW9tA-lOG5MYnAITl38tkjaVRJwJdcHrf99Z1eSi0Ja-mKBNLpmZzwzu5rvQ-gdZABZqGRIImZ6hMmMEpWqnMTC9KyNcy6pa3AeX4rzKRvN-GwPNXRHtQJXD5Z2jk9qupx__PVj-xkc_lPVMh53VxCEXKMYlFUQjgWUQ_voECKTdIwG4zrdr7C-I8U814cDYSeQTER1H83Dl2nFKg_p38pD739FeW8p1Ueo4RF6UqeWuF_ZwlO0Z4tn6FFFNrl9jr4NYcjLn2SzwGWOv9sCuzlYnOCrCzLpf7nGrMvx3LrZM-yZw3FhbzwsOB5PLrrTOdx-5UiYcL7xQulduVhtX6Dp8Ozr4JzUrAok46FcE9rLI5WwPEljGrLIUMWgqIBfxQ2jJpEmFGniyogetyoLhfMjLnPZsyBvKH2JDoqysK8QNjnPIwspDFwTfN-kvhFYcZ445UsZoLDRn85qyHHHfDHXfumbxrrSuQada69zLQL0fnfOogLc-Kf0qRuWnaQDy_Y7yuWNrn1Pi4TTBP5pEkYlE0qmqZQ2NKmgIkwZywJ00gyqbgxQuwV5h90maIDe7g6D77kFlaSw5cbLQPVMJWUBki1jaD1Q-0hxd-tRvBUVXEp4gw-N2fy5-d9f-PV_PMwxehw5K_bAvSfoYL3c2DeQOq3TDtqXM9lBh_3-6HoE29Ozy6sJ7B2IQcdPR3S8x_wGXbYTpg
linkProvider	Scholars Portal
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VRQguiKcwLbBIcAIrtveVPSBUKFFCmwqVBuW22N51qZTaoU5U5U_xG5lZ26lSid568SGe-DH77ey3M54ZQt4CA8hjreIw4TYKucpZqDNdhH1pI-f6hVAME5zHR3I44d-mYrpF_na5MPhZZWcTvaG2VY4-8h4GSLGWlmSf5n9C7BqF0dWuhUYDiwO3uoQtW_1xtA_j-y5JBl9PvgzDtqtAmItYLUIWFYlOeZFmfRbzxDLNgVTDUQvLmU2VjWWWIo2OhNN5LBFHQhUqciBv0QEKJv8OLLwRbvbUVK19Ohg147Fuc3Mi1u_VsD5iDhvs-IApSNipbax_vk3ABre9_mXmtfCsX_UGD8mDlq7SvQZfj8iWKx-Tu00Dy9UT8nMAMKouw-WcVgU9dyVFvy5N6fdReLy3_4PynqAzhx456ruR09Kd-lLjdHw86k1mcPsaGzvRYumFsrNqXq-eksmt6PQZ2S6r0j0n1BaiSBzQIrgm2BOb-eRiLUTKkWupgMSd_kzeljHHbhoz48PprG8anRvQufE6NzIg79f_mTdFPG6U_ozDspbEAtz-h-ri1LTz2chUsBSsV8qZ4lKrLFPKxTaTTMYZ53lAdrtBNa1VqM0VhgPyZn0a5jMGadLSVUsvA8BiivGAqA0wbDzQ5pny7LevDK6ZFErBG3zoYHN18_-_8Iubn_U1uTc8GR-aw9HRwQ65nyCYfU3gXbK9uFi6l8DKFtkrPxUo-XXbc-8fEOZAuA
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9NADD9NnUC8ID5FYcAhwRNETXJfuQeENrpqZayqCkV7O5LcZUwqSVlbTf3X-OuwL0mnTmJve-lD4zaJz_b9bJ9tQt4CAsgjraIg5jYMuMpZoDNdBIm0oXNJIRTDAueTkTya8i-n4nSH_G1rYfBYZWsTvaG2VY4x8h4mSLGXlmS9ojkWMe4PPs3_BDhBCjOt7TiNWkSO3foS3LfFx2Ef1vpdHA8Ov38-CpoJA0EuIrUMWFjEOuVFmiUs4rFlmgPAhk8tLGc2VTaSWYqQOhRO55FEmRKqUKEDeovBUDD_uwq9og7ZPTgcjSebCA_m0Hikm0qdkCW9BeyWWNEG_h_gBgl-29Zu6IcGbCHd6-c0ryVr_R44eEDuN-CV7tfS9pDsuPIRuVOPs1w_Jj8GIFTVZbCa06qgv11JMcpLUzoeBpP9_jfKe4LOHMbnqJ9NTkt35huP05PJsDedwe0XOOaJFitPlJ1X88X6CZneClefkk5Zle4ZobYQRewAJMF_gnWxmS811kKkHJGX6pKo5Z_Jm6bmOFtjZnxynSWm5rkBnhvPcyO75P3mN_O6pceN1Ae4LBtKbMftv6guzkyj3UamgqVgy1LOFJdaZZlSLrKZZDLKOM-7ZK9dVNPYiIW5kuguebO5DNqNKZu0dNXK04B_zhTjXaK2hGHrgbavlOe_fJ9wzaRQCt7gQys2Vzf__ws_v_lZX5O7oHfm63B0_ILci1GWfYPgPdJZXqzcS4Boy-xVowuU_Lxt9fsH-fhGUw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Follow-up+of+men+with+a+PI-RADS+4%2F5+lesion+after+negative+MRI%2FUltrasound+fusion+biopsy&rft.jtitle=Scientific+reports&rft.au=Kornienko%2C+Kira&rft.au=Reuter%2C+Miriam&rft.au=Maxeiner%2C+Andreas&rft.au=G%C3%BCnzel%2C+Karsten&rft.date=2022-08-10&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft.spage=13603&rft_id=info:doi/10.1038%2Fs41598-022-17260-6&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon